Evidence map›Paper›PMID 40739681›Full record

ReviewCurrent topics in medicinal chemistry2026

The Vital Role of Long Non-coding RNA SUMO1P3 in the Regulation of Human Cancer: Current Perspectives and Future Challenges.

Jingjie Yang, Yuzhang Wei, Chengran Gao, Zihang Wang, Yulong Liu, Haodong He, Hao Zhou, Guihua Liao, Gang Zhou, Chengfu Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingjie YangHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China.ORCID 0009-0007-5055-5900
Yuzhang WeiCollege of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
Chengran GaoCollege of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
Zihang WangCollege of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
Yulong LiuCollege of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
Haodong HeHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China.
Hao ZhouCollege of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
Guihua LiaoCollege of Traditional Chinese Medicine, China Three Gorges University & Yichang Hospital of Traditional Chinese Medicine, Yichang 443002, China.
Gang ZhouCollege of Traditional Chinese Medicine, China Three Gorges University & Yichang Hospital of Traditional Chinese Medicine, Yichang 443002, China.
Chengfu YuanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China.

Funding

Joint Fund Project of Hubei Province Natural Science Foundation in China 2024AFD261National Natural Science Foundation of China 82174035, 82374107Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China 2023KZL01
6 · The paper itself

Abstract

Small Ubiquitin-like Modifier 1 Pseudogene 3 (SUMO1P3) is a novel long non-coding RNA (lncRNA) located at the 1q23.2 locus of the human chromosome. Recent evidence indicates that SUMO1P3 is aberrantly upregulated in nine types of human cancer and functions as an oncogene. Elevated SUMO1P3 expression is strongly associated with unfavorable clinicopathological features and poor prognosis in eight cancer types. Mechanistically, SUMO1P3 functions as a miRNA sponge, an epigenetic regulator, and directly interacting with proteins. It activates key signaling pathways, such as the Wnt/β-catenin and AKT pathways, and regulates Epithelial- Mesenchymal Transition (EMT), which facilitates cancer progression and therapy resistance. Due to its diverse functional roles, SUMO1P3 emerges as a promising diagnostic and prognostic biomarker, as well as a potential therapeutic target in precision oncology. This review provides a comprehensive summary of current research on SUMO1P3, highlighting its regulatory mechanisms, biological functions, and clinical significance in cancer biology.

Indexed as

NeoplasmsRNA, Long NoncodingHumansRNA, Long NoncodingBiomarkerCancerlncRNASUMO1SUMO1P3Targeted therapy

Identifiers

PMID40739681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.